Beijing Minhai Biotechnology Co., Ltd

Beijing Minhai Biotechnology Co.,Ltd.is a modern biotechnology enterprise specialized in vaccine R&D, production and distribution. Minhais mission is to provide safe, stable and affordable vaccines; increase immunization coverage, reduce the incidence of infectious disease and mortality; protect human health. Minhai was founded in June 2004, with a registered capital of 200 million RMB, at No.35, Simiao Road, Bio-medicine Industry Park in Daxing District, Beijing, which has a leading R&D center and a modern vaccine manufacturing site composed of over 60,000 m2 GMP compliant workshops, equipped with advanced large-scale bacteria vaccine production line and virus vaccine production line. Until 2015, there are three commercialized vaccine products in China, including Hib conjugate vaccine, MR vaccine and DTaP-Hib vaccine. DTaP-Hib vaccine, which is independently developed by Minhai, is the first domestic quatri-valent vaccine. There are over 20 vaccines in Minhais pipeline (from p...